Distinct designs, complementary strategies: Tendyne and SAPIEN M3 in transcatheter mitral valve replacement

Q: What is the clinical evidence from this study?

Study design: Review. Population: Symptomatic moderate-to-severe or severe mitral regurgitation or mitral valve dysfunction associated with mitral annular calcification. Intervention: Transcatheter mitral valve replacement (Tendyne and SAPIEN M3 systems).

Q: What does this research mean for the field?

The Tendyne and SAPIEN M3 systems offer distinct, complementary device designs and procedural strategies that address different anatomical and patient selection criteria in transcatheter mitral valve replacement. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Zhaoyang Ye; Stephanie Sellers; David J. Meier; Tim Attmann; Xiling Zhang; Thomas Puehler; Nina Pommert; Jacob Voran; Won Kim; G. Warnecke; Derk Frank; Georg Lutter

doi:10.3389/fcvm.2026.1966140

November 11, 2026Frontiers in Cardiovascular MedicineOpen Access

Distinct designs, complementary strategies: Tendyne and SAPIEN M3 in transcatheter mitral valve replacement

View Full Paper

Ask AI

Bookmark

Share

Key result

Tendyne and SAPIEN M3 provide approved TMVR options for severe MR unsuitable for surgery or TEER.

Why the study?

The Tendyne and SAPIEN M3 systems are clinically approved TMVR platforms for selected patients with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair, requiring evaluation of their distinct designs, patient selection criteria, and outcomes to guide clinical decision-making.

Key Points

To comprehensively compare the design mechanisms, procedural features, clinical outcomes, and patient selection criteria of the Tendyne and SAPIEN M3 transcatheter mitral valve replacement systems.
Comparative review analyzing technical configurations, procedural delivery profiles, and clinical evidence for both the Tendyne and SAPIEN M3 platforms.
Evaluation of patient eligibility parameters, including anatomical suitability for patients deemed unsuitable for conventional open surgery or transcatheter edge-to-edge repair.
Synthesis of emerging horizons focusing on tissue-engineered valvular stents and biodegradable scaffolds to improve long-term prosthetic durability.
The Tendyne and SAPIEN M3 systems represent clinically approved platforms holding CE Mark and FDA approval for transcatheter mitral valve replacement in selected patients.
The SAPIEN M3 platform employs a dedicated nitinol dock that encircles the native leaflets to create a secure landing zone for a 29 mm balloon-expandable cobalt-chromium bioprosthetic valve delivered via a 23F guide sheath.
Both systems serve complementary clinical niches for symptomatic moderate-to-severe or severe mitral regurgitation and mitral annular calcification when surgery or edge repair is unfeasible, with future iterations focusing on biodegradable and tissue-engineered scaffolds.

Structured PICO

P

Population

Patients with symptomatic moderate-to-severe or severe mitral regurgitation or MAC-associated mitral valve dysfunction deemed unsuitable for surgery or transcatheter edge-to-edge repair.

I

Intervention

Transcatheter mitral valve replacement (TMVR) using the Tendyne or SAPIEN M3 systems (29 mm balloon-expandable cobalt-chromium frame with three bovine pericardial leaflets and a nitinol dock delivered via transseptal approach).

Limitations

Long-term durability has not been established for the SAPIEN M3 valve
Current metallic prostheses have limitations in prosthetic durability and biocompatibility
Safety and effectiveness of the SAPIEN M3 system have not been established for patients with LVEDD >= 75 mm, commissural distance >= 50 mm, LVEF < 25%, severe RV dysfunction, or severe pulmonary hypertension
Current metallic prostheses have limitations in prosthetic durability and biocompatibility.
Long-term durability has not been established for the SAPIEN M3 valve.
Safety and effectiveness of the SAPIEN M3 system have not been established in patients with LVEDD >= 75 mm, commissural distance >= 50 mm, LVEF < 25%, severe RV dysfunction, history of heart transplant, severe pulmonary hypertension, or blood dyscrasias.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This review and device instruction summary outlines the design, procedural steps, and patient selection criteria for the Tendyne and SAPIEN M3 transcatheter mitral valve replacement systems in patients with severe mitral regurgitation unsuitable for surgery or TEER.

Abstract

Transcatheter mitral valve replacement (TMVR) has emerged as a transcatheter treatment option for selected patients with mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair. Among dedicated TMVR devices, the Tendyne and SAPIEN M3 systems are the two clinically approved tech platforms with CE Mark and FDA approval. We comprehensively dissect their distinct design features, procedural characteristics, clinical outcomes, and associated complication profiles. Furthermore, we evaluate their respective patient selection criteria and long-term prognostic implications to facilitate evidence-based clinical decision-making for patients with severe MR. Beyond current metallic prostheses, this review extends to the future horizons of TMVR, specifically highlighting the emerging paradigm of tissue-engineered valvular stents and biodegradable scaffolds as potential solutions to overcome current limitations in prosthetic durability and biocompatibility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2026) conducted a review in Symptomatic moderate-to-severe or severe mitral regurgitation or mitral valve dysfunction associated with mitral annular calcification. Transcatheter mitral valve replacement (Tendyne and SAPIEN M3 systems) was evaluated. Tendyne and SAPIEN M3 transcatheter mitral valve replacement systems are clinically approved options for severe mitral regurgitation patients unsuitable for surgery or edge-to-edge repair.

synapsesocial.com/papers/6af5bf07e94012e8747ad998 https://doi.org/10.3389/fcvm.2026.1966140

View Full Paper

Ask AI

Bookmark

Share

Distinct designs, complementary strategies: Tendyne and SAPIEN M3 in transcatheter mitral valve replacement

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Distinct designs, complementary strategies: Tendyne and SAPIEN M3 in transcatheter mitral valve replacement

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading